Purine nucleoside phosphorylase inhibitors (PNP-Is) were developed to ablate transformed lymphocytes. However, only some patients with leukemia benefit from PNP-Is. We provide a molecular explanation: the deoxyribonucleoside triphosphate (dNTP) hydrolase SAM and HD domain-containing protein 1 (SAMHD1) prevents the accumulation of toxic dNTP levels during purine nucleoside phosphorylase inhibition. We propose PNP-Is for targeted therapy of patients with acquired mutations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671039 | PMC |
| http://dx.doi.org/10.1080/23723556.2020.1804308 | DOI Listing |
Publication Analysis
Top Keywords
purine nucleoside
8
nucleoside phosphorylase
8
pnp inhibitors
4
inhibitors selectively
4
selectively kill
4
kill cancer
4
cancer cells
4
cells lacking
4
lacking samhd1
4
samhd1 purine
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!